Dicot AB
Research Dicot AB (DICOT) on Bullrun: market cap SEK 728.42M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerDICOT
- ExchangeST
- CountrySweden
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencySEK
- Market capSEK 728.42M
- Financial periodQ1 2026
- RevenueSEK 0
- Net income-SEK 14.80M
- Free cash flow-SEK 12.80M
Valuation Snapshot
latest market cap is SEK 728.42M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | n/a | n/a | n/a | n/a | -0.04 | SEK 69.19M | n/a | SEK 73.36M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-24 | SEK 728.42M | n/a | n/a | n/a |
About Dicot AB
Dicot Pharma AB engages in the development of pharmaceutical products in Sweden. It develops LIB-01 that is in Phase 2a clinical trial for the treatment of erectile dysfunction and under medical discovery for treating premature ejaculation. The company was formerly known as Dicot AB (publ) and changed its name to Dicot Pharma AB in May 2024. Dicot Pharma AB was incorporated in 2015 and is based in Uppsala, Sweden.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Dicot AB's market cap?
Dicot AB's market capitalization is SEK 728.42M.
What does Dicot AB do?
Dicot Pharma AB engages in the development of pharmaceutical products in Sweden. It develops LIB-01 that is in Phase 2a clinical trial for the treatment of erectile dysfunction and under medical discovery for treating premature ejaculation. The company was formerly known as Dicot AB (publ) and changed its name to Dicot Pharma AB in May 2024. Dicot Pharma AB was incorporated in 2015 and is based in Uppsala, Sweden.